Dr. Nedelkov has been at the forefront of clinical assays and technology development for over 25 years. Dr. Nedelkov received his Ph.D. in Biochemistry from Arizona State University in 1997, and after a year as a Postdoctoral Associate at Yale University, Dr. Nedelkov joined Intrinsic Bioprobes where over the span of 15 years he progressed through the ranks to ultimately become Scientific Director and CEO of the company, leading the early commercialization efforts in technology development for targeted proteomics and protein biomarkers. Following an acquisition by Thermo Scientific in 2011, Dr. Nedelkov joined the Biodesign Institute at Arizona State University in 2013 as a group leader of the Molecular Biomarkers Unit, focusing on proteoform biomarker discovery, validation, and translation. In 2017 Dr. Nedelkov started Isoformix with the intent of commercializing protein isoforms assays, and more recently focusing on discovering novel targets for the treatment of Alzheimer's disease. Dr. Nedelkov has authored over 100 peer reviewed scientific articles, presented at more than 60 scientific meetings, has 4 issued patents, and has served as a principal investigator on numerous NIH grants.